Literature DB >> 10964947

Selective activation of mGlu4 metabotropic glutamate receptors is protective against excitotoxic neuronal death.

V Bruno1, G Battaglia, I Ksiazek, H van der Putten, M V Catania, R Giuffrida, S Lukic, T Leonhardt, W Inderbitzin, F Gasparini, R Kuhn, D R Hampson, F Nicoletti, P J Flor.   

Abstract

Activation of group III metabotropic glutamate receptors (mGluR4, mGluR6, mGluR7, and mGluR8) has been established to be neuroprotective in vitro and in vivo. To disclose the identity of the receptor subtype(s) that exert(s) the protective effect, we have used group III agonists in combination with mGluR4 subtype-deficient mice (-/-). In cortical cultures prepared from wild-type (+/+) mice and exposed to a toxic pulse of NMDA, the selective group III agonist (+)-4-phosphonophenylglycine [(+)-PPG] reversed excitotoxicity with an EC(50) value of 4.9 microm, whereas its enantiomer (-)-PPG was inactive. This correlated closely with the potency of (+)-PPG in activating recombinant mGluR4a. In cortical neurons from -/- mice, (+)-PPG showed no protection against the NMDA insult up to 300 microm, whereas group I/II mGluR ligands still retained their protective activity. Classical group III agonists (l-2-amino-4-phosphonobutyrate and l-serine-O-phosphate) were also substantially neuroprotective against NMDA toxicity in +/+ and heterozygous (+/-) cultures but were inactive in -/- cultures. Interestingly, -/- cultures were more vulnerable to low concentrations of NMDA and showed higher extracellular glutamate levels compared with +/+ cultures. We have also examined neurodegeneration induced by intrastriatal infusion of NMDA in wild-type or mGluR4-deficient mice. Low doses of (R,S)-PPG (10 nmol/0.5 microl) substantially reduced NMDA toxicity in +/+ mice but were ineffective in -/- mice. Higher doses of (R,S)-PPG were neuroprotective in both strains of animals. Finally, microdialysis studies showed that intrastriatal infusion of NMDA increased extracellular glutamate levels to a greater extent in -/- than in +/+ mice, supporting the hypothesis that the mGluR4 subtype is necessary for the maintenance of the homeostasis of extracellular glutamate levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964947      PMCID: PMC6772963     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  44 in total

1.  Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.

Authors:  J A Monn; M J Valli; S M Massey; R A Wright; C R Salhoff; B G Johnson; T Howe; C A Alt; G A Rhodes; R L Robey; K R Griffey; J P Tizzano; M J Kallman; D R Helton; D D Schoepp
Journal:  J Med Chem       Date:  1997-02-14       Impact factor: 7.446

2.  Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors.

Authors:  V Bruno; G Battaglia; A Kingston; M J O'Neill; M V Catania; R Di Grezia; F Nicoletti
Journal:  Neuropharmacology       Date:  1999-02       Impact factor: 5.250

3.  A novel splice variant of a metabotropic glutamate receptor, human mGluR7b.

Authors:  P J Flor; H Van Der Putten; D Rüegg; S Lukic; T Leonhardt; M Bence; G Sansig; T Knöpfel; R Kuhn
Journal:  Neuropharmacology       Date:  1997-02       Impact factor: 5.250

4.  Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction.

Authors:  N Okamoto; S Hori; C Akazawa; Y Hayashi; R Shigemoto; N Mizuno; S Nakanishi
Journal:  J Biol Chem       Date:  1994-01-14       Impact factor: 5.157

5.  CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding.

Authors:  S Litschig; F Gasparini; D Rueegg; N Stoehr; P J Flor; I Vranesic; L Prézeau; J P Pin; C Thomsen; R Kuhn
Journal:  Mol Pharmacol       Date:  1999-03       Impact factor: 4.436

6.  Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells.

Authors:  S Wu; R A Wright; P K Rockey; S G Burgett; J S Arnold; P R Rosteck; B G Johnson; D D Schoepp; R M Belagaje
Journal:  Brain Res Mol Brain Res       Date:  1998-01

7.  LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats.

Authors:  J Konieczny; K Ossowska; S Wolfarth; A Pilc
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1998-10       Impact factor: 3.000

8.  Metabotropic glutamate receptor agonist-induced hyperpolarizations in rat basolateral amygdala neurons: receptor characterization and ion channels.

Authors:  K H Holmes; N B Keele; V L Arvanov; P Shinnick-Gallagher
Journal:  J Neurophysiol       Date:  1996-11       Impact factor: 2.714

9.  Oxygen or glucose deprivation-induced neuronal injury in cortical cell cultures is reduced by tetanus toxin.

Authors:  H Monyer; R G Giffard; D M Hartley; L L Dugan; M P Goldberg; D W Choi
Journal:  Neuron       Date:  1992-05       Impact factor: 17.173

10.  Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 4.

Authors:  P J Flor; S Lukic; D Rüegg; T Leonhardt; T Knöpfel; R Kuhn
Journal:  Neuropharmacology       Date:  1995-02       Impact factor: 5.250

View more
  25 in total

1.  Metabotropic glutamate receptor-mediated signaling in neuroglia.

Authors:  David J Loane; Bogdan A Stoica; Alan I Faden
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-01-11

2.  The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection.

Authors:  Corrado Corti; Giuseppe Battaglia; Gemma Molinaro; Barbara Riozzi; Anna Pittaluga; Mauro Corsi; Manolo Mugnaini; Ferdinando Nicoletti; Valeria Bruno
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

3.  The ups and downs of hippocampal metabotropic glutamate receptors: ramifications for epileptogenesis and cognitive impairment following status epilepticus.

Authors:  Lisa R Merlin
Journal:  Epilepsy Curr       Date:  2008 Mar-Apr       Impact factor: 7.500

4.  Activation of Type 4 Metabotropic Glutamate Receptor Attenuates Oxidative Stress-Induced Death of Neural Stem Cells with Inhibition of JNK and p38 MAPK Signaling.

Authors:  Zhichao Zhang; Wen Ma; Li Wang; Hanshi Gong; Yumei Tian; Jianshui Zhang; Jianxin Liu; Haixia Lu; Xinlin Chen; Yong Liu
Journal:  Stem Cells Dev       Date:  2015-09-01       Impact factor: 3.272

5.  Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP.

Authors:  Jesper Mosolff Mathiesen; Nannette Svendsen; Hans Bräuner-Osborne; Christian Thomsen; M Teresa Ramirez
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 6.  Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.

Authors:  Marion S Mercier; David Lodge
Journal:  Neurochem Res       Date:  2014-08-22       Impact factor: 3.996

7.  Restraint stress differentially regulates inflammation and glutamate receptor gene expression in the hippocampus of C57BL/6 and BALB/c mice.

Authors:  Monica Sathyanesan; Jacob M Haiar; Michael J Watt; Samuel S Newton
Journal:  Stress       Date:  2017-03-08       Impact factor: 3.493

8.  Increased seizure susceptibility in mice lacking metabotropic glutamate receptor 7.

Authors:  G Sansig; T J Bushell; V R Clarke; A Rozov; N Burnashev; C Portet; F Gasparini; M Schmutz; K Klebs; R Shigemoto; P J Flor; R Kuhn; T Knoepfel; M Schroeder; D R Hampson; V J Collett; C Zhang; R M Duvoisin; G L Collingridge; H van Der Putten
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

Review 9.  Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Authors:  Hilary Highfield Nickols; P Jeffrey Conn
Journal:  Neurobiol Dis       Date:  2013-09-27       Impact factor: 5.996

Review 10.  Glutamate receptors as therapeutic targets for Parkinson's disease.

Authors:  Kari A Johnson; P Jeffrey Conn; Colleen M Niswender
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.